Wayne Koberstein - Executive Editor

Wayne Koberstein

Wayne Koberstein

Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.

WAYNE'S WORK

A Progress Report On The 2016 Companies To Watch
A Progress Report On The 2016 Companies To Watch   There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.  Continue Reading...
The Enterprisers: CohBar - Producing Mitochondria Medicine
The Enterprisers: CohBar - Producing Mitochondria Medicine Why shouldn’t our mitochondria want us to live long, prospering in good health? Why shouldn’t they — as symbiotic microbes turned cellular organelles with their own mini-genomes — carry genes that help ensure our healthful survival?  Continue Reading...
The Wider Net — JPM Healthcare Conference 2017 In SF
The Wider Net — JPM Healthcare Conference 2017 In SF At the JPM conference, I spend the bulk of my time meeting with a string of companies, but as various as they are, they all share the common challenge of risk and uncertainty in the development of human therapeutics. For us in the press, it can be tempting to toss companies into easy categories such as size, stage of research, market cap  - but then, it’s fun and interesting to let the patterns among the companies emerge spontaneously ...  Continue Reading...
Companies To Watch: Ritter Pharmaceuticals On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance  Continue Reading...
Janssen Immunology — Science & Market Drivers
Janssen Immunology — Science & Market Drivers In this exclusive with Sue Dillon, Ph.D., head of Janssen Immunology, she talks candidly about topics such as how the company marries the precommercial and commercial functions.  Continue Reading...
Night Of Light: California Life Science Association (CLSA)
Night Of Light: California Life Science Association (CLSA) Because I live only a day-trip away from San Francisco, it is convenient for me to travel there for industry events — a trek always accompanied by reflective reveries for the hometown of my film-student days. So, for the third time since June, and with another week scheduled for early January, I am once again city-bound, leaving home mid-day and getting into my hotel in plenty of time to make the 5:30 PM reception for the annual Pantheon...  Continue Reading...
Company Leaders Tackle The New Year’s Toughest Macro Challenges
Company Leaders Tackle The New Year’s Toughest Macro Challenges We posed some difficult questions to biopharma-company leaders on tough political, economic, and business challenges — those likely to become even tougher for the industry in 2017. The bravest among the invited answered our queries with thoughtful responses regarding thorny issues such as Brexit and the U.S. election, drug pricing and reimbursement, new life science business models, and the industry’s technological future.  Continue Reading...
BIO Shines In San Francisco
BIO Shines In San Francisco This year, the BIO Investor Forum (#BIF16) in San Francisco enjoyed its largest turnout ever, basked in the light and warmth of a dynamic industry that may not solve all of the world’s problems, but shines upon us, a salubrious star. Will the industry’s star shine upon everyone, or leave most of humanity in the shadows?  Continue Reading...
Why Now Is A Pivotal Time For Rare-Disease Pharma Catabasis
Why Now Is A Pivotal Time For Rare-Disease Pharma Catabasis There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.  Continue Reading...
Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care
Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care Medicine is becoming more targeted, and most of the innovation is coming in the development of new targeted medicines, which tend to be biologics disproportionately so their application is more complex and most often begins with a specialist,” says David Meeker, executive VP and head of Sanofi Genzyme.  Continue Reading...
NOVAVAX: Scouting Past The Long Trail To Market
NOVAVAX: Scouting Past The Long Trail To Market Clinical challenges lurk all along the pathway for any company developing new vaccine candidates and technology — and that goes at least twice for Novavax. As we go to press with this, the company is dealing with an anxious investment community about the “failed” Phase 3 trial of its RSV F vaccine in older adults, for protection against respiratory syncytial virus (RSV). (See “Press-Time Thunder.”)  Continue Reading...
Company To Watch: ViewPoint Therapeutics
Company To Watch: ViewPoint Therapeutics Dr. Leah Makley, president and CSO, founded ViewPoint based on five years of research she conducted in the lab of cofounder Dr. Jason Gestwicki, where all work is dedicated to protein misfolding, primarily in neurodegenerative diseases such as Alzheimer’s.  Continue Reading...
IO: Science Still Drives The Business
IO: Science Still Drives The Business How much science does a business person need to know? In this industry, the more the better. Without at least an excellent layperson’s understanding of the company’s scientific underpinnings, a life science executive will remain vulnerable to the greatest of all hazards in managing the business — today’s news.  Continue Reading...
How Rebiotix Avoids The Typical Biopharma Startup Missteps
How Rebiotix Avoids The Typical Biopharma Startup Missteps A straightforward purpose and premise were the words that came to mind in my first impression of this company. Lee Jones, the CEO and cofounder of Rebiotix, describes building the company in an “of course, this is how you do it” manner. The larger issue — whether the company’s Microbiota Restoration Therapy (MRT) platform will succeed in a somewhat besieged field — can only be resolved over time. But it will most...  Continue Reading...
Cancer Immunotherapy - Simpler Or More Complex?
Cancer Immunotherapy - Simpler Or More Complex? A summary of the issues that recently fired up the IO field.  Continue Reading...
Companies To Watch: Quark Pharmaceuticals
Companies To Watch: Quark Pharmaceuticals Having passed through much of the proof-of-concept gauntlet, the company and its products’ next big test will come in its Phase 3 trials, where the concept meets uncertainty at the macro scale.  Continue Reading...
Companies To Watch: Enteris BioPharma
Companies To Watch: Enteris BioPharma “When you’re working for other companies, there are two disadvantages — one, you don’t have full control of your destiny; two, the work tends to come in peaks and valleys.”  Continue Reading...
Life Science Leadership In Action: RespireRx
Life Science Leadership In Action: RespireRx Suffocation seldom gets the credit it deserves for causing death in so many conditions — from sleep apnea to heart failure to drug overdose. But if you view the large variety of those cases at a higher resolution, you will see “respiratory failure” as the common final, fatal effect.  Continue Reading...
Living With Pricing
Living With Pricing Life Science Leader Launches a Search for Common Ground  Continue Reading...
How Tunitas Therapeutics Is Tackling Novel Treatment And Prevention Of The Most Serious Allergies
How Tunitas Therapeutics Is Tackling Novel Treatment And Prevention Of The Most Serious Allergies Tackling novel treatment and prevention of the most serious allergies with new science and seasoned business talent.  Continue Reading...
Finding The Common Ground On Drug Pricing
Finding The Common Ground On Drug Pricing Go inside the room of our closed-door session on solutions for the drug-pricing dilemma. It included panelists from three essential perspectives: pharma, payers, and patients.  Continue Reading...
BIO Still Delivers
BIO Still Delivers If the BIO International Convention did nothing but assemble the 16,000 people who came to this year’s meeting in San Francisco, simply giving them a space to talk, that alone would be a great achievement.  Continue Reading...
Takeda’s New Plans For Worldwide Growth
Takeda’s New Plans For Worldwide Growth Christophe Weber, the current and still nascent CEO of Takeda, is also an unavoidable symbol of the company’s current transformation into a global organization as the first non-Japanese person to head a Japan-based pharma company.  Continue Reading...
Developing New Therapeutics For Progressive MS
Developing New Therapeutics For Progressive MS This is the concluding installment of our three-part series on new therapeutic mechanisms for neurodegenerative diseases. Here, as in the first two parts, we have brought together a “virtual roundtable” comparing the views of key scientific opinion leaders with some of the companies developing new therapeutics for progressive MS. (See Part One, “Aiming at Alzheimer’s,” March 2016, and Part Two, “Parsing Out...  Continue Reading...
An Absent Life Science Blogger’s Backstory
An Absent Life Science Blogger’s Backstory Alas, I am a specialized ignoramus, or dilettante; aka, a journalist. To ask even the most basic questions about the series topic — generally, new therapeutic approaches to neurodegenerative diseases — I first put myself through a veritable college course on the subject, reading and rereading through a tall (cyber) pile of related scientific, medical, and commercial literature. And yet, it is not the unseen labor I regret, but the...  Continue Reading...
Companies To Watch: Addex Therapeutics
Companies To Watch: Addex Therapeutics Targeting Parkinson’s dyskinesia and other rare CNS disorders with a novel receptor-binding approach.  Continue Reading...
John Lechleiter Discusses How Lilly Will Meet Its Performance Goals
John Lechleiter Discusses How Lilly Will Meet Its Performance Goals John Lechleiter discusses how Lilly will meet its performance goals.  Continue Reading...
Companies To Watch: Osel
Companies To Watch: Osel Live biotherapeutics to restore microbiomes — in midstage development for vaginal and urinary conditions — with a special focus on women’s health  Continue Reading...
InVivo Therapeutics: Taking On Spinal-Cord Injury
InVivo Therapeutics: Taking On Spinal-Cord Injury Not everyone knows someone with a spinal-cord injury. I did. We met as teenagers, shared a few years as friends but lost touch when I drifted to the opposite end of the country  Continue Reading...
Hot New Therapeutic MOAs Versus Neurodegenerative Diseases
Hot New Therapeutic MOAs Versus Neurodegenerative Diseases Experts Discuss Opportunities In Parkinson’s.  Continue Reading...
Hot New Therapeutic MOAs versus Neurodegenerative Diseases
Hot New Therapeutic MOAs versus Neurodegenerative Diseases Science leads business in this long dormant but awakening area. Part one of three parts: Aiming at Alzheimer’s  Continue Reading...
Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma?
Abbey Meyers: Did The Pioneer Of Orphan Drugs Spark Biopharma? Industry Explorers Blaze On: Abbey Meyers  Continue Reading...
Companies To Watch: Egalet - Developing Safer Opioids In A Market Under Siege
Companies To Watch: Egalet - Developing Safer Opioids In A Market Under Siege Developing Safer Opioids In A Market Under Siege  Continue Reading...
Companies To Watch Roundup
Companies To Watch Roundup An Update On All The Companies We Profiled In 2015  Continue Reading...
Companies To Watch: Symic Biomedical
Companies To Watch: Symic Biomedical Needed treatments in vascular injury, osteoarthritis, and maybe more, cleverly targeting the dynamic extracellular matrix.  Continue Reading...
Catalyst CEO Shares Product Pricing Context
Catalyst CEO Shares Product Pricing Context The following is an excerpt from the interview with Catalyst Pharmaceuticals’ Co-Founder, President and CEO Pat McEnany for our January 2016 installment of Companies to Watch. Catalyst epitomizes the pricing issues so many companies now face with new, possible breakthrough or essential drugs they in-license or acquire the rights to develop, yet its situation is also unique in many ways.  Continue Reading...
Amarantus: Risen From The Ashes
Amarantus: Risen From The Ashes One startup’s bad luck in the clinic leads to the creation of  a new company — Amarantus  Continue Reading...
Companies To Watch: Catalyst Pharmaceuticals
Companies To Watch: Catalyst Pharmaceuticals Reemerging with a licensed drug for a rare neuromuscular disease — and treading carefully to set its price  Continue Reading...
Write Thinking — Biopharma At the Turn of the Year
Write Thinking — Biopharma At the Turn of the Year Writing is reinforced thinking. It is a stronger, more constructive way of moving through the thought world. Because I am a trade journalist covering the life science industry, all of those things tend to appear to me in industry terms. Take the drug-pricing debate, for example.     Continue Reading...
Startups & Outsourcing — Opposite Poles or Virtual Partners?
Startups & Outsourcing — Opposite Poles or Virtual Partners? Let’s face it, finding the money often captures all but a few crumbs of the typical startup CEO’s attention. Laser-sharp illustrations in the company’s dog-and-pony show may present its scientific platform with convincing clarity and purpose, but traditionally, investment conferences have not been a place where the dollar-hungry startup talks about the infrastructure it must build or hire to turn its science into a medical...  Continue Reading...
Investment Experts Forecast Gains Over Pains In 2016 For Life Sciences
Investment Experts Forecast Gains Over Pains In 2016 For Life Sciences This fall, during the weeks following the great Turing-ignited clash over drug pricing and the consequential plunge in biopharma stocks and valuations, we captured the thoughts of six leaders in life science investment capital, which fuels drug development by hundreds of new companies every year.  Continue Reading...
Codagenix, A Tiny Start-Up Ready To Take On The Goliaths Of The Vaccine Industry
Codagenix, A Tiny Start-Up Ready To Take On The Goliaths Of The Vaccine Industry One egg per person. That is what it takes to produce a flu vaccine. The standard, predominant method has not changed in more than 70 years.  Continue Reading...
Companies To Watch: Vascular Pharmaceuticals
Companies To Watch: Vascular Pharmaceuticals Vascular Pharmaceuticals is developing a drug to treat diabetic nephropathy. With its partner Janssen, the company has moved its lead mAb compound through preclinical and Phase 1 studies and is now beginning a Phase 2 program. Janssen has the option to acquire Vascular upon completion of the Phase 2 trial.  Continue Reading...
Reliving the Past, Shaping the Future of Cancer Therapy
Reliving the Past, Shaping the Future of Cancer Therapy A news item on AZ’s new “crowdsourcing” approach to cancer-drug treatment. The report uncritically hailed the program as a veritable revolution in cancer therapy that could yield greatly improved results from combinations of traditional chemotherapeutics and, presumably, other approved drugs with different modalities such as molecular-pathway targeting.  Continue Reading...
Mucosal Vaccines: The First Hope For Fighting Respiratory Syncytial Virus (RSV)
Mucosal Vaccines: The First Hope For Fighting Respiratory Syncytial Virus (RSV) Needle-free, mucosal vaccines that trigger a two-fisted immune response offer the first hope for fighting RSV — and raising the bar in vax technology.  Continue Reading...
Warning: Cancer Immunotherapy Information
Warning: Cancer Immunotherapy Information If you can say that you completely understand how immunotherapy works in cancer, please feel free to skip this small primer. But for the vast crowd that constitutes the rest of us, we include this basic explanation.   Continue Reading...
Immuno-Oncology — The Year’s News In Science
Immuno-Oncology — The Year’s News In Science In 2014, many of the most encouraging studies of checkpoint blockade went public at the annual ASCO (American Society of Clinical Oncology) meeting. This year, even more positive studies of new checkpoint inhibitors were reported.  Continue Reading...
Combo Immuno-Oncology R&D Programs — Recent & Ongoing By careful estimate, companies will have a large number of combination cancer immunotherapy trials in planning or execution as of Jan. 1, 2016.  Continue Reading...
Pfizer: A Pure Power Play For Innovative Pharma
Pfizer: A Pure Power Play For Innovative Pharma A show of hands, please. How many of you reading this know about Pfizer’s split into several separate pharmaceutical businesses? Just in case you missed it, on Jan. 1, 2014, Pfizer formally divided into two separate business units that together possess three different “operating segment” groups.  Continue Reading...
Combination Cancer Immunotherapy: A 2015 Update
Combination Cancer Immunotherapy: A 2015 Update What a difference a year makes. Last year, beginning in September, we ran a series that addressed the challenges and opportunities of using new agents to rally the immune system against cancer. In most cases, we were talking about the checkpoint blockers such as ipilimumab and tremelimumab, inhibiting the checkpoint CTLA-4, and nivolumab, pembrolizumab, and pidilizumab, which have a multimodal effect on another target, PD-1. Checkpoints are...  Continue Reading...
More From Wayne Koberstein